TY - JOUR
KW - Leprosy
KW - Erythema Nodosum Leprosum
KW - Leprosy reaction
KW - Biological Therapy
AU - Gomide L
AU - Brufatto J
AU - Kucarz T
AU - Velho P
AU - França A
AB - <p><strong>Background</strong></p>

<p>Erythema nodosum leprosum (ENL) is an immunological inflammatory reaction requiring precise management. Recalcitrant cases, their refractoriness to conventional therapy, and the adverse effects of standard treatments underline the need to explore alternative therapeutic options.</p>

<p><strong>Methods</strong></p>

<p>We conducted a retrospective study of five patients treated with secukinumab between January 2023 and January 2025.</p>

<p><strong>Results</strong></p>

<p>Patients showed clinical improvement with a reduced ENL frequency, neuritis relief, and corticosteroid sparing.</p>

<p><strong>Conclusions</strong></p>

<p>Secukinumab appears to be a promising corticosteroid-sparing option for ENL, with a favorable safety profile. Further studies are required to confirm the efficacy and long-term safety of this treatment regimen.</p>

BT - Revista da Sociedade Brasileira de Medicina Tropical
C1 - https://www.ncbi.nlm.nih.gov/pubmed/41036900
DA - 01/2025
DO - 10.1590/0037-8682-0118-2025
J2 - Rev Soc Bras Med Trop
LA - eng
M3 - Article
N2 - <p><strong>Background</strong></p>

<p>Erythema nodosum leprosum (ENL) is an immunological inflammatory reaction requiring precise management. Recalcitrant cases, their refractoriness to conventional therapy, and the adverse effects of standard treatments underline the need to explore alternative therapeutic options.</p>

<p><strong>Methods</strong></p>

<p>We conducted a retrospective study of five patients treated with secukinumab between January 2023 and January 2025.</p>

<p><strong>Results</strong></p>

<p>Patients showed clinical improvement with a reduced ENL frequency, neuritis relief, and corticosteroid sparing.</p>

<p><strong>Conclusions</strong></p>

<p>Secukinumab appears to be a promising corticosteroid-sparing option for ENL, with a favorable safety profile. Further studies are required to confirm the efficacy and long-term safety of this treatment regimen.</p>

PY - 2025
SP - 1
EP - 5
T2 - Revista da Sociedade Brasileira de Medicina Tropical
TI - Managing leprosy reactions with secukinumab: Insights from a case series.
UR - https://pmc.ncbi.nlm.nih.gov/articles/PMC12479038/pdf/1678-9849-rsbmt-58-e0118-2025.pdf
VL - 58
SN - 1678-9849
ER -